Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open Label, Randomized, Multicenter Study Evaluating the Safety and Efficacy of 25 mg and 50 mg Doses of Proellex to Assess Recurrence of Symptoms in the Treatment of Symptomatic Uterine Fibroids

NCT00874302 is registered in ClinicalTrials.gov with Repros Therapeutics Inc. as lead sponsor.

NCT NCT00874302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00874302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open Label, Randomized, Multicenter Study Evaluating the Safety and Efficacy of 25 mg and 50 mg Doses of Proellex to Assess Recurrence of Symptoms in the Treatment of Symptomatic Uterine Fibroids
Lead sponsor
Repros Therapeutics Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
Not reported
Completion date
Not reported
Enrollment
0 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

uterine fibroids